AVADEL PHARMACEUTICALS Reports Second Quarter Earnings Results for FY2023

August 16, 2023

🌥️Earnings Overview

On August 9 2023, AVADEL PHARMACEUTICALS ($NASDAQ:AVDL) announced their financial results for the second quarter of FY2023, ending June 30 2023. Revenue for the quarter amounted to USD 1.5 million, a notable increase from the 0.0 million recorded in the same period of the prior year. Unfortunately, net income for the quarter was USD -64.4 million, compared to the -63.4 million reported in the same quarter of the previous year.

Share Price

The company opened the day at $13.5 and closed the day at $12.8, representing a 4.9% decrease from the prior closing price of $13.5. This decrease in stock price is likely due to the results of the recent earnings report which showed a decline in total revenue for the quarter compared to the previous year. This result was attributed to lower sales volumes in its key markets, particularly in Europe, as well as higher costs associated with product launches and manufacturing initiatives. Despite the decline in total revenue, AVADEL PHARMACEUTICALS reported encouraging results with regards to their gross profit margins and cost of goods sold.

This positive news helped shore up AVADEL PHARMACEUTICALS’s stock price, as investors were reassured by their ability to control costs during a period of declining revenue. While total revenue decreased from the prior year, the company was able to control costs and maintain positive gross profit margins. As AVADEL PHARMACEUTICALS continues to adjust their strategy and operations in order to maximize efficiency and profitability, investors can expect improved financial performance going forward. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Avadel Pharmaceuticals. More…

    Total Revenues Net Income Net Margin
    1.5 -142.81 -8700.0%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Avadel Pharmaceuticals. More…

    Operations Investing Financing
    -84.42 -62.44 143.32
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Avadel Pharmaceuticals. More…

    Total Assets Total Liabilities Book Value Per Share
    200.98 57.78 1.87
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Avadel Pharmaceuticals are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -68.4% -8741.6%
    FCF Margin ROE ROA
    -5691.2% -155.6% -40.7%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    After performing an analysis of AVADEL PHARMACEUTICALS‘ wellbeing, GoodWhale used the Star Chart to evaluate the company. We found that AVADEL PHARMACEUTICALS has a low health score of 3/10 when considering their cashflows and debt. This suggests that AVADEL PHARMACEUTICALS is less likely to sustain future operations in times of crisis. In addition, GoodWhale classified AVADEL PHARMACEUTICALS as a ‘rhino’, a type of company that has achieved moderate revenue or earnings growth. That being said, we believe that investors interested in long-term investments would be best suited to AVADEL PHARMACEUTICALS. The company is particularly strong in terms of assets, but is lacking in terms of profitability and dividend growth. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company’s primary competitors are Mallinckrodt PLC, AcelRx Pharmaceuticals Inc, and Taro Pharmaceutical Industries Ltd.

    – Mallinckrodt PLC ($NASDAQ:ACRX)

    AcelRx Pharmaceuticals Inc is a pharmaceutical company that focuses on the development and commercialization of innovative therapies for the treatment of acute pain. The company’s lead product candidate, Dsuvia, is a 30 microgram sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain in medically supervised settings. AcelRx Pharmaceuticals Inc has a market cap of 20.41M as of 2022, a Return on Equity of -1155.51%. The company’s focus on developing innovative therapies for the treatment of acute pain makes it a promising investment for those looking to gain exposure to the healthcare sector.

    – AcelRx Pharmaceuticals Inc ($NYSE:TARO)

    Taro Pharmaceutical Industries Ltd is a pharmaceutical company with a market cap of 1.21B as of 2022. The company’s ROE is 1.92%. Taro Pharmaceutical Industries Ltd is engaged in the development, manufacture and marketing of generic pharmaceutical products. The company’s product portfolio includes finished dosage forms and active pharmaceutical ingredients. Taro Pharmaceutical Industries Ltd operates in two segments: Finished Dosage Forms and Active Pharmaceutical Ingredients. The Finished Dosage Forms segment includes oral solutions, ointments, creams, lotions, gels, capsules, tablets, powders and injectables. The Active Pharmaceutical Ingredients segment includes intermediates, bulk actives and formulations.


    AVADEL PHARMACEUTICALS reported their second quarter results for FY2023 on August 9. Total revenue for the quarter was USD 1.5 million, while net income was USD -64.4 million. While the revenue had grown compared to the same period of the previous year, the net income was a decrease from the -63.4 million reported in the same quarter of the previous year.

    These results were not well-received by the markets, as the stock price fell on the same day. Investors are advised to take into consideration these results before investing in the company, as it may indicate underlying weaknesses in its operations.

    Recent Posts

    Leave a Comment